国际免疫学杂志
國際免疫學雜誌
국제면역학잡지
INTERNATIONAL JOURNAL OF IMMUNOLOGY
2014年
3期
250-254
,共5页
高媛媛%侯军君%温荔媛%徐睿瑞%孙立春
高媛媛%侯軍君%溫荔媛%徐睿瑞%孫立春
고원원%후군군%온려원%서예서%손립춘
非小细胞肺癌%转化生长因子β-1%表皮生长因子受体%免疫组化
非小細胞肺癌%轉化生長因子β-1%錶皮生長因子受體%免疫組化
비소세포폐암%전화생장인자β-1%표피생장인자수체%면역조화
Non-small cell lung cancer%Transforming growth factorβ-1%Epidermal growth factor receptor%Immunohistochemistry
目的 研究非小细胞肺癌(NSCLC)中转化生长因子β-1(TGFβ-1)与表皮生长因子受体(EGFR)蛋白的表达情况,探讨二者与NSCLC临床病理特征及患者生存的关系.方法 选取114例NSCLC组织,通过常规石蜡包埋行免疫组织化学染色,检测TGFβ-1与EGFR的表达情况.并对其与NSCLC临床特征关系进行分析.结果 TGFβ-1在NSCLC中的阳性表达率为48.25％.TGFβ-1的表达与NSCLC的组织学类型和EGFR的表达相关(分别为x2=11.679,P=0.001;x2=6.883,P=0.009),而与年龄、性别、淋巴结转移、分化程度及AJCC分期无关.EGFR的表达仅与组织学类型相关(x2=15.497,P ＜0,001),而与其它病理特征无相关性.TGFβ-1阳性表达的NSCLC有较好的生存预后,具有统计学意义(x2=4.066,P=0.044).在EGFR阳性表达的肺癌患者中,TGFβ-1表达阳性的患者具有较长的总生存期,具有统计学意义(x2=5.768,P=0.016).结论 TGFβ-1可能作为NSCLC尤其是EGFR阳性表达的患者较好的预后因子可为临床判断患者的预后和进行个体化治疗提供帮助.
目的 研究非小細胞肺癌(NSCLC)中轉化生長因子β-1(TGFβ-1)與錶皮生長因子受體(EGFR)蛋白的錶達情況,探討二者與NSCLC臨床病理特徵及患者生存的關繫.方法 選取114例NSCLC組織,通過常規石蠟包埋行免疫組織化學染色,檢測TGFβ-1與EGFR的錶達情況.併對其與NSCLC臨床特徵關繫進行分析.結果 TGFβ-1在NSCLC中的暘性錶達率為48.25％.TGFβ-1的錶達與NSCLC的組織學類型和EGFR的錶達相關(分彆為x2=11.679,P=0.001;x2=6.883,P=0.009),而與年齡、性彆、淋巴結轉移、分化程度及AJCC分期無關.EGFR的錶達僅與組織學類型相關(x2=15.497,P ＜0,001),而與其它病理特徵無相關性.TGFβ-1暘性錶達的NSCLC有較好的生存預後,具有統計學意義(x2=4.066,P=0.044).在EGFR暘性錶達的肺癌患者中,TGFβ-1錶達暘性的患者具有較長的總生存期,具有統計學意義(x2=5.768,P=0.016).結論 TGFβ-1可能作為NSCLC尤其是EGFR暘性錶達的患者較好的預後因子可為臨床判斷患者的預後和進行箇體化治療提供幫助.
목적 연구비소세포폐암(NSCLC)중전화생장인자β-1(TGFβ-1)여표피생장인자수체(EGFR)단백적표체정황,탐토이자여NSCLC림상병리특정급환자생존적관계.방법 선취114례NSCLC조직,통과상규석사포매행면역조직화학염색,검측TGFβ-1여EGFR적표체정황.병대기여NSCLC림상특정관계진행분석.결과 TGFβ-1재NSCLC중적양성표체솔위48.25％.TGFβ-1적표체여NSCLC적조직학류형화EGFR적표체상관(분별위x2=11.679,P=0.001;x2=6.883,P=0.009),이여년령、성별、림파결전이、분화정도급AJCC분기무관.EGFR적표체부여조직학류형상관(x2=15.497,P ＜0,001),이여기타병리특정무상관성.TGFβ-1양성표체적NSCLC유교호적생존예후,구유통계학의의(x2=4.066,P=0.044).재EGFR양성표체적폐암환자중,TGFβ-1표체양성적환자구유교장적총생존기,구유통계학의의(x2=5.768,P=0.016).결론 TGFβ-1가능작위NSCLC우기시EGFR양성표체적환자교호적예후인자가위림상판단환자적예후화진행개체화치료제공방조.
Objective To investigate the expression of transforming growth factorβ-1 (TGFβ-1) and epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) and its relationship with tumor characteristics and survival of patients with NSCLC.Methods The expression of TGFβ-1 and EGFR in 114 NSCLC patients was evaluated by immunohistochemical technique.The relationship between patient outcome and clinical pathologic characters was studied.Results Positive immunostaining of TGFβ-1 was detected in 48.25％ of NSCLC samples.TGFβ-1 expression correlated with histological type and EGFR expression (x2 =11.679,P =0.001 ;x2 =6.883,P =0.009,respectively).The expression of TGFβ-1 was not correlated with gender,age,lymph node,differentiation and AJCC.EGFR expression significantly related with histological type(x2 =15.497,P ＜ 0.001),but not associated with clinicopathological features.Patients with positive TGFβ-1 expression had better prognosis (x2 =4.066,P =0.044).In EGFR positive patients,positive TGFβ-1 expression was favorable prognostic factor.Patients with TGFβ-1 positive expression shown longer overall survival(x2 =5.768,P =0.016).Conclusion TGFβ-1 may be a favourable prognostic factor for the patients with NSCLC,especially for the patients with positive EGFR,the results may help to predict the prognosis and optimize the strategies for individualized therapy.
